Adage Capital Partners GP »

Sab Biotherapeutics shares owned by Adage Capital Partners GP

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Adage Capital Partners GP from 13F filings

Historical chart of Adage Capital Partners GP investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Adage Capital Partners GP consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Adage Capital Partners GP

Quarter filed Position value Share count Share price at filing
2026-03-31 $13M 3.4M 3.83

More positions owned by Adage Capital Partners GP

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl C (GOOG)
Tesla Motors (TSLA)
Eli Lilly & Co. (LLY)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
ConocoPhillips (COP)
JPMorgan Chase & Co. (JPM)
Johnson & Johnson (JNJ)
Revolution Medicines (RVMD)

View all positions for Adage Capital Partners GP

Top funds holding Sab Biotherapeutics

Vivo Capital
Caligan Partners
Perceptive Advisors
Commodore Capital
RA Capital Management
Balyasny Asset Management
Adage Capital Partners GP
Millennium Management
Woodline Partners
Vanguard Capital Management
Sessa Capital IM
Vanguard Group
Boothbay Fund Management
Ameriprise Financial
Ensign Peak Advisors

View all funds holding Sab Biotherapeutics